Extended-release divalproex sodium for mood stabilization

Pharmacotherapy

Volumn 24, Issue 9, 2004, Pages 1147-1153

  Stoner, Steven C ^a,b   Dubisar, Beth M ^b,c   Lea, Jessica W ^a,b   Marken, Patricia A ^a   Ramlatchman, Leonard V ^b   Reynolds, James B ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b NW Missouri Psychiat Rehab Ctr ^*  (United States)

^c SOUTHERN UNIVERSITY   (United States)

Author keywords

Delayed release; Divalproex sodium; Extended release; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; ALOPECIA; ANTICONVULSANT THERAPY; APPETITE DISORDER; ARTICLE; ASTHENIA; ATAXIA; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPEPSIA; EXTENDED RELEASE FORMULATION; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MENTAL DISEASE; MOOD DISORDER; NAUSEA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT GAIN;

ADULT; ANTIMANIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DELAYED-ACTION PREPARATIONS; HUMANS; LONG-TERM CARE; MIDDLE AGED; MISSOURI; MOOD DISORDERS; PROSPECTIVE STUDIES; VALPROIC ACID;

EID: 4344710508     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.13.1147.38088     Document Type: Article

References (33)

1. Hirschfeld RM, Bowden CL, Gitlin MJ, et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159(4, suppl):4-50.
2. Sachs GS, Printz DJ, Kahn DA, et al. The expert consensus guideline series: medication treatment of bipolar disorder 2000. Special report. Postgrad Med 2000;1-104.
3. Kane JM, Leucht S, Carpenter D, Docherty JP. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64(suppl 12):5-97.
4. Lehman AF, Lieberman JA, Dixon LB, et al. American Psychiatric Association practice guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(2):2-56.
5. Citrome L, Levine J, Allingham B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994-1998. Psychiatr Serv 2000;51(5):634-8.
6. Citrome L, Levine J, Allingham B. Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health. Psychiatr Q 1998;69(4):283-300.
7. Bowden CL, Brugger AM, Swann AC, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994;271(12):918-24.
8. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry 1990;147(4):431-4.
9. Jann MW, Garrelts JC, Ereshefsky L, Saklad SR. Alternative drug therapies for mania: a literature review. Drug Intell Clin Pharm 1984;18:577-89.
10. Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ. Predictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993;13(4):280-2.
11. Deltito JA. The effect of valproate on bipolar spectrum temperamental disorders. J Clin Psychiatry 1993;54(8):300-4.
12. Freeman TW, Clothier JL, Pazzaglia P, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149(1):108-11.
13. Gerner RH, Stanton A. Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine. J Clin Psychopharmacol 1992;12(1):57S-63.
14. Kastner T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol 1993;13(6):448-51.
15. McElroy SL, Keck PE. Treatment guidelines for valproate in bipolar and schizoaffective disorders. Can J Psychiatry 1993;38(suppl 2):S62-6.
16. Stoll AL, Banov M, Kolbrener M, et al. Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994;14(5):311-13.
17. Wilcox J. Divalproex sodium in the treatment of aggressive behavior. Ann Clin Psychiatry 1994;6(1):17-20.
18. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas consensus conference panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002;63(4):288-99.
19. Abbott Laboratories. Depakote (divalproex sodium) package insert. North Chicago, IL; 2002.
20. Keck PE, McElroy SL, Tugral KC, Bennett JA. Valproate oral loading in the treatment of acute mania. J Clin Psychiatry 1993;54(8):305-8.
21. Pope HG, McElroy SL, Keck PE, Hudson JI. Valproate in the treatment of acute mania. Arch Gen Psychiatry 1991;48:62-7.
22. Rosenfeld WE, Leppik IE, Gates JR, Mireles RE. Valproic acid loading during intensive monitoring. Arch Neurol 1987;44:709-10.
23. Hirschfeld RM, Allen MH, McEvoy JP, Keck PE, Russell JM. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999;60(12):815-18.
24. McEvoy JP, Scheifler PL, Frances A. Expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(suppl II):4-72.
25. Wassef AA, Dott SG, Harris A, et al. Randomized, placebo-controlled pilot study of DVPX sodium in the treatment of acute exacerbations of chronic schizophrenia. J Clin Psychopharmacol 2000;20(3):357-61.
26. Bogan AM, Brown ES, Suppes T. Efficacy of DVPX therapy for schizoaffective disorder. J Clin Psychopharmacol 2000;20(5):520-2.
27. Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003;28:182-92.
28. Abbott Laboratories. Depakote ER (extended-release divalproex sodium) package insert. North Chicago, IL; 2003.
29. Dutta A, Zhang Y, Selness DS, et al. Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers. Epilepsy Res 2002;49:1-10.
30. Home RL, Cunanan C. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium. J Clin Psychopharmacol 2003;23(2):176-81.
31. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
32. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986;22:343-81.
33. Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-9.